Company intelligence / Profile preview

Prime Biome

United States

Ownership: Private
Development stage: Other

Overview

Prime Biome is a dietary supplement positioned as a microbiome-focused ‘gut reset’ system, targeting gut, skin, and potentially neurological health through a blend of spore-forming probiotics, prebiotics, and botanical adaptogens. The company claims clinical improvements in digestion, skin clarity, inflammation, and systemic symptoms based on customer experiences and references to scientific research, but there is no evidence of regulatory approval for disease treatment and no direct citation of peer-reviewed, independent clinical trials for the marketed product[1][3][5].

Therapeutic areas: GastroenterologyMetabolic DisordersOtherDermatologyPsychiatry
Modalities: Microbial therapySmall moleculeBotanical extractPrebioticSpore-forming probiotic
Industry: Food & Nutrition

Beyond the preview

Go deeper on Prime Biome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prime Biome.

Explore the full profile